An in vitro model of drug-resistant seizures for selecting clinically effective antiseizure medications in Febrile Infection-Related Epilepsy Syndrome
暂无分享,去创建一个
[1] A. Vezzani,et al. Neuroimmunology of status epilepticus , 2023, Epilepsy & Behavior.
[2] D. Henshall,et al. Increased expression of the ATP‐gated P2X7 receptor reduces responsiveness to anti‐convulsants during status epilepticus in mice , 2021, British journal of pharmacology.
[3] E. Aronica,et al. CXCL1-CXCR1/2 signaling is induced in human temporal lobe epilepsy and contributes to seizures in a murine model of acquired epilepsy , 2021, Neurobiology of Disease.
[4] Elizabeth M. Wells,et al. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort , 2020, Annals of clinical and translational neurology.
[5] Elizabeth M. Wells,et al. Proposal to optimize evaluation and treatment of Febrile infection‐related epilepsy syndrome (FIRES): A Report from FIRES workshop , 2020, Epilepsia open.
[6] R. Tulsawani,et al. Loss of Protection by Antiepileptic Drugs in Lipopolysaccharide-primed Pilocarpine-induced Status Epilepticus is Mediated via Inflammatory Signalling , 2020, Neuroscience.
[7] N. Pietrafusa,et al. New‐onset refractory status epilepticus and febrile infection‐related epilepsy syndrome , 2020, Developmental medicine and child neurology.
[8] K. Kothur,et al. Etiology is the key determinant of neuroinflammation in epilepsy: Elevation of cerebrospinal fluid cytokines and chemokines in febrile infection‐related epilepsy syndrome and febrile status epilepticus , 2019, Epilepsia.
[9] A. Vezzani,et al. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy , 2019, Nature Reviews Neurology.
[10] S. Barbieri,et al. Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection–related epilepsy syndrome , 2019, Epilepsia open.
[11] C. Howe,et al. Functional deficiency in endogenous interleukin‐1 receptor antagonist in patients with febrile infection‐related epilepsy syndrome , 2019, Annals of neurology.
[12] K. Chu,et al. Tocilizumab treatment for new onset refractory status epilepticus , 2018, Annals of neurology.
[13] L. Lagae,et al. Proposed consensus definitions for new‐onset refractory status epilepticus (NORSE), febrile infection‐related epilepsy syndrome (FIRES), and related conditions , 2018, Epilepsia.
[14] E. Aronica,et al. Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies , 2018, Neuropathology and applied neurobiology.
[15] A. Vezzani,et al. Febrile Infection–Related Epilepsy Syndrome: Clinical Review and Hypotheses of Epileptogenesis , 2016, Neuropediatrics.
[16] E. Wirrell,et al. Febrile infection‐related epilepsy syndrome treated with anakinra , 2016, Annals of neurology.
[17] G. Burmester,et al. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA , 2016, Journal of clinical pharmacology.
[18] Yi Wang,et al. Interleukin-1 receptor is a target for adjunctive control of diazepam-refractory status epilepticus in mice , 2016, Neuroscience.
[19] B. Widemann,et al. Abstract 1411: Plasma and cerebrospinal fluid pharmacokinetics of tocilizumab in a nonhuman primate model , 2016 .
[20] A. Vezzani,et al. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability , 2015, Neuropharmacology.
[21] Y. Takahashi,et al. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[22] F. Gao,et al. Acute lipopolysaccharide exposure facilitates epileptiform activity via enhanced excitatory synaptic transmission and neuronal excitability in vitro , 2014, Neuropsychiatric disease and treatment.
[23] E. Aronica,et al. The dual role of TNF-α and its receptors in seizures , 2013, Experimental Neurology.
[24] H. Chugani,et al. Successful surgical treatment of an inflammatory lesion associated with new-onset refractory status epilepticus. , 2013, Neurosurgical focus.
[25] M. Sahin,et al. Febrile infection–related epilepsy syndrome (FIRES): Pathogenesis, treatment, and outcome , 2011, Epilepsia.
[26] T. Bártfai,et al. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures , 2011, Brain, Behavior, and Immunity.
[27] Annamaria Vezzani,et al. Inflammation and prevention of epileptogenesis , 2011, Neuroscience Letters.
[28] M. Ōsawa,et al. Blood concentrations of midazolam in status epilepticus using an appropriate condition of HPLC , 2010, Pediatrics international : official journal of the Japan Pediatric Society.
[29] N. Rothwell,et al. Interleukin-1 Receptor Antagonist Penetrates Human Brain at Experimentally Therapeutic Concentrations , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[30] E. Aronica,et al. The IL-1β system in epilepsy-associated malformations of cortical development , 2006, Neurobiology of Disease.
[31] J. Velíšková,et al. Susceptibility of immature and adult brains to seizure effects , 2004, The Lancet Neurology.
[32] T. Morimoto,et al. Long-term medical, educational, and social prognoses of childhood-onset epilepsy: a population-based study in a rural district of Japan , 2000, Brain and Development.
[33] U. Heinemann,et al. Effects of standard anticonvulsant drugs on different patterns of epileptiform discharges induced by 4-aminopyridine in combined entorhinal cortex–hippocampal slices , 2000, Brain Research.